Singapur - anglès - HSA (Health Sciences Authority)

fresenius kabi (singapore) pte ltd - general hospital - for extended platelet storage and plasma collection, rbc collection and mnc collection.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

stark medical - 42339 - root separator - surgical instrument designed for wedging apart the roots of a mandibular tooth.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aero healthcare - 13544 - toe separator - a non-sterile device intended to be used to separate toes. it aids in the prevention of bunions or pain produced by friction. this is a reusable device.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

nutripath pty ltd -

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

edwards group pty ltd -

Israel - anglès - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - solution for infusion - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.herceptin should only be used in patients with metastatic gastric cancer whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory fish+ result, or ihc 3+, as determined by an accurate and validated assay

Tanzània - anglès - Tanzania Medicinces & Medical Devices Authority

crown healthcare (t) ltd, tanzania - evacuated blood collection tube ivd,clot activator/gel separator -